Contract Loss on a Pharmaceutical Contract Manufacturing Agreement
First written in FY2017. 13 of 14 entries say "Restated". Latest entry: FY2025-H1.
7 other companies' latest entry also says "Restated".
- FY2025-H1RestatedAnnual report
「No new business or other risks arose during the six months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company states that no new losses have arisen and no material changes have occurred in relation to the contract loss on the pharmaceutical manufacturing agreement. - FY2024-Q2RestatedAnnual report
「No new business or other risks arose during the cumulative second-quarter period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company states that no new losses have arisen and no material changes have occurred in relation to the contract loss on the pharmaceutical manufacturing agreement. - FY2024-Q1RestatedAnnual report
「There were no newly arising business or other risks during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company states that no new losses have arisen and no material changes have occurred in relation to the contract loss on the pharmaceutical manufacturing agreement. - FY2022-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third-quarter period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company states that no new losses have arisen and no material changes have occurred in relation to the contract loss on the pharmaceutical manufacturing agreement. - FY2022-Q2RestatedAnnual report
「No new business or other risks arose during the cumulative second-quarter period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company states that no new losses have arisen and no material changes have occurred in relation to the contract loss on the pharmaceutical manufacturing agreement. - FY2021-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third-quarter period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company states that no new losses have arisen and no material changes have occurred in relation to the contract loss on the pharmaceutical manufacturing agreement. - FY2021-Q2RestatedAnnual report
「No new business or other risks arose during the cumulative second-quarter period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company states that no new losses have arisen and no material changes have occurred in relation to the contract loss on the pharmaceutical manufacturing agreement. - FY2020-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third-quarter period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company states that no new losses have arisen and no material changes have occurred in relation to the contract loss on the pharmaceutical manufacturing agreement. - FY2020-Q2RestatedAnnual report
「No new business or other risks arose during the cumulative second-quarter period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company states that no new losses have arisen and no material changes have occurred in relation to the contract loss on the pharmaceutical manufacturing agreement. - FY2020-Q1RestatedAnnual report
「No new business or other risks arose during the cumulative first-quarter period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company states that no new losses have arisen and no material changes have occurred in relation to the contract loss on the pharmaceutical manufacturing agreement. - FY2019-Q1RestatedAnnual report
「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that no new losses have arisen and no material changes have occurred in relation to the contract loss on the pharmaceutical manufacturing agreement. - FY2018-Q3RestatedAnnual report
「No new business or other risks arose during the nine months ended 31 December. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company states that no new risks have arisen and no material changes have occurred during the current quarter in relation to the contract loss on the pharmaceutical manufacturing agreement. - FY2018-Q1RestatedAnnual report
「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company states that no new risks have arisen and no material changes have occurred during the current quarter in relation to the contract loss on the pharmaceutical manufacturing agreement. - FY2017MaterialisedAnnual report
「The contract manufacturing agreement for pharmaceuticals received by the Company is a loss-making contract because the costs the Company is expected to incur in the future exceed the amount of consideration expected under the contract. Accordingly, the Company recorded ¥6,451 million as an expense for provision for contract losses in the current fiscal year, against losses expected to arise over the contract period.」
The Company determined that future costs under the pharmaceutical manufacturing agreement would exceed the contract consideration and recorded a ¥6,451 million provision for contract losses.